Skip to main content
. Author manuscript; available in PMC: 2023 Jan 9.
Published in final edited form as: Eur J Pain. 2017 Aug 14;22(1):84–93. doi: 10.1002/ejp.1092

Figure 2. Effect of desformylflustrabromine on nicotine-induced antinociception.

Figure 2.

A range of doses of desformylflustrabromine (dFBr), an α4β2* nAChR PAM, on nicotine treatment of CCI mice (A), and sham mice (B) were tested using von Frey test. For this reason, dFBr (1, 3, 6, and 9 mg/kg) or vehicle (0.9% saline) was injected subcutaneously 15 min before nicotine (0.5 mg/kg) or vehicle (0.9% saline) treatment. The potentiation effect of dFBr was also investigated with different doses of nicotine in CCI (C) and sham (D) mice. The highest dose of dFBr (9 mg/kg) or vehicle (0.9% saline) was injected subcutaneously 15 min before nicotine (0.1, 0.25, and 0.5 mg/kg) or vehicle (0.9% saline) treatment. The percentage of reversal (E) was calculated at 10 min after nicotine administration in CCI-treated mice. * P < 0.05 vs saline-saline treatment. # P < 0.05 vs saline-nicotine treatment. Data reflect mean ± SEM, n = 6 mice/group. BL: Baseline